Compare Duolingo Inc (DUOL) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Duolingo Inc trades at $151 (market cap $7.10B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 8.2× Duolingo Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| DUOL | TAK | |
|---|---|---|
Market Cap | $7.10B | $58.16B |
Volume | 922,471 | 2,467,530 |
Sector | Technology | Health |
52-Week High | $341.08 | $19.05 |
52-Week Low | $90.03 | $13.23 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $5.87B | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DUOL trades at $151.72, up 2.42% today, with a bullish technical outlook and strong support near $149. The company reported robust fundamentals, with Q2 2026 EPS beating expectations at $0.66 versus $0.604, and revenue growth accelerating to $1.04 billion in 2025. Operating cash flow surged to $387.82 million, reflecting strong operational efficiency.
The stock presents a compelling growth story with high net margins of 35.87% and consistent earnings beats, though valuation multiples like EV/EBITDA of 33.96 suggest premium pricing. Key risks include insider selling and competitive pressures in edtech. Analyst consensus is mixed with a $140.63 price target, indicating cautious optimism amid near-term volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
